Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Castagnetti, Fausto, Breccia, Massimo, Gugliotta, Gabriele, Martino, Bruno, D’Adda, Mariella, Stagno, Fabio, Carella, Angelo Michele, Avanzini, Paolo, Tiribelli, Mario, Trabacchi, Elena, Visani, Giuseppe, Gobbi, Marco, Salvucci, Marzia, Levato, Luciano, Binotto, Gianni, Capalbo, Silvana Franca, Bochicchio, Maria Teresa, Soverini, Simona, Cavo, Michele, Martinelli, Giovanni, Alimena, Giuliana, Pane, Fabrizio, Saglio, Giuseppe, Rosti, Gianantonio, Baccarani, Michele
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2016
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5046649/
https://ncbi.nlm.nih.gov/pubmed/27470600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.144949
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars